Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 12, 2009, Pages 1560-1562

  Hinderaker, S G ^a   Ysykeeva, J ^b   Veen, J ^b   Enarson, D A ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Project HOPE   (Kyrgyzstan)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Adverse reactions; Anti tuberculosis drugs; Kyrgyzstan

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ABDOMINAL PAIN; ARTICLE; COLLAPSE; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; HEALTH PROGRAM; HUMAN; INCIDENCE; JAUNDICE; KYRGYZSTAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SHOCK; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

ADULT; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; HUMANS; KYRGYZSTAN; PYRAZINAMIDE; RIFAMPIN; SPUTUM; TUBERCULOSIS;

EID: 74949089732     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Girling D J. Adverse effects of anti-tuberculosis drugs. Drugs 1982; 23: 56-74.
2. Rieder H L. Interventions for tuberculosis control and elimination. Chemotherapy. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002: 15-93.
3. Bass J B Jr, Farer L S, Hopewell P C, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
4. Peloquin C A. Clinical pharmacology of the anti-tuberculosis drugs. In: Davies P D O, ed. Clinical tuberculosis. London, UK: Arnold, 2003: pp 171-190.
5. Alisherov A S, ed. Guidelines for TB control in the Kyrgyz Republic. 2nd ed. Bishkek, Kyrgyzstan: National Tuberculosis Programme, 2006.
6. United Nations Joint Programme on HIV/AIDS/World Health Organization. 2008 report on the global AIDS epidemic. Geneva, Switzerland: WHO and UNAIDS, 2008.
7. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland: 2008.
8. Gonzalez Montaner L J, Dambrosi A, Manassero M, Dambrosi V M. Adverse effects of anti-tuberculosis drugs causing changes in treatment. Tubercle 1982; 63: 291-294.
9. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
10. Marra F, Marra C A, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11: 868-875.
11. Hasker E, Khodjikhanov M, Usarova S, et al. Drug prescribing practices for tuberculosis in Uzbekistan. Int J Tuberc Lung Dis 2009; 13: 1405-1410.